Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

NEXIUM 10 MG — DIN 02300524

ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) : 10 MG · ASTRAZENECA CANADA INC · GRANULES FOR SUSPENSION, DELAYED RELEASE · wholesale supply in Canada

Health Canada status: MARKETED

What is NEXIUM?

NEXIUM 10 MG contains ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02300524, held by ASTRAZENECA CANADA INC, supplied as GRANULES FOR SUSPENSION, DELAYED RELEASE for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Jan-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is NEXIUM used for?

NEXIUM (esomeprazole delayed release tablets or esomeprazole delayed release granules) is indicated in adults (18 years of age and above) for treatment of conditions where a reduction in gastric acid secretion is required such as: reflux esophagitis, maintenance treatment of patients with reflux esophagitis, nonerosive reflux disease (NERD) (i.e. heartburn and regurgitation), healing of NSAID*-associated gastric ulcers, reduction of risk of NSAID-associated gastric ulcers, treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome, Helicobacter pylori (H. pylori) eradication. NEXIUM, in combination with clarithromycin and amoxicillin, is indicated for the treatment of patients with duodenal ulcer disease associated with Helicobacter pylori infection to eradicate the H. pylori and heal ulcers. For pediatrics (1-17 years of age), NEXIUM (esomeprazole) is indicated for treatment of conditions where a reduction in gastric acid secretion is required such as: reflux esophagitis, nonerosive reflux disease (NERD) (i.e. heartburn and regurgitation).

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Esomeprazole cost around the world?

Esomeprazole is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
Australiaex-manufacturer11143AUD███.██
South Africasingle exit price4863ZAR███.██
AustriaKVP (Kassenverkaufspreis)2346EUR███.██
Saudi Arabiapublic1528SAR███.██
MoroccoPPV (public price)720MAD███.██
Bahrainretail (max)918BHD███.██
Luxembourgreimbursement1616EUR███.██
Greeceproducer price (ex-factory)1414EUR███.██
Czechiamax producer price (ex-factory)311CZK███.██
United Kingdomhospital44GBP███.██

363 pack listings across 150 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Esomeprazole pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

Is there a generic Esomeprazole in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

16 holders have a Canadian DIN containing Esomeprazole, across 46 DINs, of which 26 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
ASTRAZENECA CANADA INC33NEXIUM, NEXIUM - 20MG, NEXIUM - 40MGSourceable in Canada
LABORATOIRE RIVA INC.62ESOMEPRAZOLE DR, RIVA-ESOMEPRAZOLE, RIVA-ESOMEPRAZOLE DRSourceable in Canada
MYLAN PHARMACEUTICALS ULC62MYL-ESOMEPRAZOLE, MYLAN-ESOMEPRAZOLESourceable in Canada
APOTEX INC42APO-ESOMEPRAZOLE, APO-ESOMEPRAZOLE DELAYED-RELEASESourceable in Canada
PHARMASCIENCE INC42PMS-ESOMEPRAZOLE DR, PMSC-ESOMEPRAZOLE DRSourceable in Canada
TEVA CANADA LIMITED42ESOMEPRAZOLE, TEVA-ESOMEPRAZOLESourceable in Canada
JAMP PHARMA CORPORATION22ESOMEPRAZOLESourceable in Canada
MANTRA PHARMA INC22M-ESOMEPRAZOLESourceable in Canada
PRO DOC LIMITEE22ESOMEPRAZOLESourceable in Canada
SANDOZ CANADA INCORPORATED22SANDOZ ESOMEPRAZOLESourceable in Canada
SIVEM PHARMACEUTICALS ULC22ESOMEPRAZOLESourceable in Canada
SUN PHARMA CANADA INC22TARO-ESOMEPRAZOLESourceable in Canada

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label10 MG
Dosage formGRANULES FOR SUSPENSION, DELAYED RELEASE
RouteORAL
Pack configuration (monograph)20 mg tablets in cartons of 28; 40 mg tablets in cartons of 28 or in HDPE bottles of 100 tablets; 10 mg delayed release granules for oral suspension in unit dose sachet in cartons of 30
Storagenull

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceEsomeprazole
ATC codeA02BC05
AHFS class40:50.00* ; See footnote
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02300524
DIN (unpadded, as printed on some documents)2300524
Brand nameNEXIUM
Generic / active ingredientESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) : 10 MG
Market authorization holderASTRAZENECA CANADA INC
Health Canada schedulePrescription
ATC codeA02BC05
ATC anatomical main groupA — Alimentary tract and metabolism
ATC therapeutic subgroupA02BC
Current statusMARKETED
Status date02-Jan-2008
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

Is Esomeprazole in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Active — reported by JAMP PHARMA CORPORATION, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for NEXIUM

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

26 of 46 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
APO-ESOMEPRAZOLE20 MGTABLET (DELAYED-RELEASE)APOTEX INCMARKETED02339099
APO-ESOMEPRAZOLE40 MGTABLET (DELAYED-RELEASE)APOTEX INCMARKETED02339102
ESOMEPRAZOLE20 MGTABLET (DELAYED-RELEASE)JAMP PHARMA CORPORATIONMARKETED02520699
ESOMEPRAZOLE40 MGTABLET (DELAYED-RELEASE)JAMP PHARMA CORPORATIONMARKETED02520702
ESOMEPRAZOLE40 MGTABLET (DELAYED-RELEASE)SIVEM PHARMACEUTICALS ULCMARKETED02442507
ESOMEPRAZOLE20 MGTABLET (DELAYED-RELEASE)PRO DOC LIMITEEMARKETED02394839
ESOMEPRAZOLE20 MGTABLET (DELAYED-RELEASE)SIVEM PHARMACEUTICALS ULCMARKETED02442493
ESOMEPRAZOLE40 MGTABLET (DELAYED-RELEASE)PRO DOC LIMITEEMARKETED02394847
M-ESOMEPRAZOLE20 MGTABLET (DELAYED-RELEASE)MANTRA PHARMA INCMARKETED02520109
M-ESOMEPRAZOLE40 MGTABLET (DELAYED-RELEASE)MANTRA PHARMA INCMARKETED02520117

2 · Same class — other molecules in ATC A02BC

MoleculeCanadian brandsDINsMarketedSourceable
PantoprazoleABBOTT-PANTOPRAZOLE · ACT PANTOPRAZOLE · AG-PANTOPRAZOLE · AG-PANTOPRAZOLE SODIUM · +37 more9839Yes
EsomeprazoleAPO-ESOMEPRAZOLE · APO-ESOMEPRAZOLE DELAYED-RELEASE · ESOMEPRAZOLE · ESOMEPRAZOLE DR · +14 more4626Yes
LansoprazoleAPO-LANSOPRAZOLE · AVA-LANSOPRAZOLE · DOM-LANSOPRAZOLE · LANSOPRAZOLE · +15 more4119Yes
OmeprazoleACH-OMEPRAZOLE · AG-OMEPRAZOLE DR · AHI-OMEPRAZOLE · APO-OMEPRAZOLE · +31 more5712Yes
RabeprazoleABBOTT-RABEPRAZOLE · AG-RABEPRAZOLE · APO-RABEPRAZOLE · DOM-RABEPRAZOLE EC · +15 more388Yes
DexlansoprazoleAPO-DEXLANSOPRAZOLE · DEXILANT · DEXLANSOPRAZOLE84Yes

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC A02B

ATC subgroupMoleculesDINsMarketed
A02BACimetidine · Famotidine · Famotidine, Combinations · Nizatidine · Ranitidine · +1 more23526
A02BXAlginic Acid · Pirenzepine · Sucralfate324
A02BBMisoprostol102
A02BDBismuth Subcitrate,Tetracycline And Metronidazole · Lansoprazole, Amoxicillin And Clarithromycin32

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

What else is NEXIUM called?

The same molecule, Esomeprazole, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
APO-EsomeprazoleLatinAustralia
Esomeprazole GHLatinAustralia
Esomeprazole GxPLatinAustralia
Esomeprazole RBXLatinAustralia
Esomeprazole ViatrisLatinAustralia
ESOMEPRAZOLE-WGRLatinAustralia
EsoprezeLatinAustralia
NexazoleLatinAustralia
NexoleLatinAustralia
Noxicid CapsLatinAustralia
ESOPOLELatinSaudi Arabia
EMANERALatinCzechia
GORDEX MUPSLatinBahrain
HELIDESLatinCzechia
ESOMEPRAZOLE OLIKLALatinCzechia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for NEXIUM

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02300524. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.